首页 > 最新文献

中华妇产科杂志最新文献

英文 中文
[Association between maternal pre-pregnancy body mass index and clinical pregnancy outcomes and perinatal outcomes of single live birth in frozen-thawed embryo transfer cycles]. [冻融胚胎移植周期中孕妇孕前体重指数与临床妊娠结局及单活产围产儿结局的关系]。
Pub Date : 2026-01-25 DOI: 10.3760/cma.j.cn112141-20250423-00163
H Y Hao, Y G Xiang, X J Geng, N Jia, C L Zhang, M Li, S D Zhang
<p><p><b>Objective:</b> To investigate the relationship between maternal pre-pregnancy body mass index (BMI) and clinical pregnancy outcomes and singleton live birth outcomes in frozen-thawed embryo transfer (FET) cycles. <b>Methods:</b> A total of 45 856 patients who underwent FET in Henan Provincial People's Hospital and the Second Affiliated Hospital of Zhengzhou University from January 2013 to December 2023 were retrospectively analyzed, including 15 960 singleton live births. Based on the female's BMI, they were divided into the underweight group (BMI<18.5 kg/m<sup>2</sup>), the normal weight group (BMI 18.5-<25.0 kg/m<sup>2</sup>), the overweight group (BMI 25.0-<30.0 kg/m<sup>2</sup>), and the obese group (BMI≥30.0 kg/m<sup>2</sup>). Multivariate linear models and logistic regression models were used to evaluate the effects of maternal pre-pregnancy BMI on clinical pregnancy outcomes and singleton live birth outcomes. Generalized additive model was used to fit the curve between maternal pre-pregnancy BMI and perinatal outcomes and to determine the threshold. <b>Results:</b> (1) Among 45 856 FET patients, there were 2 390 cases (5.21%) in the underweight group, 30 177 cases (65.81%) in the normal weight group, 10 835 cases (23.63%) in the overweight group, and 2 454 cases (5.35%) in the obesity group. The early abortion rate of overweight and obesity group, the clinical pregnancy rate and live birth rate of underweight group, the clinical pregnancy rate of obesity group were higher than those of normal weight group, and the live birth rate of overweight group was lower than that of normal weight group, and the differences were statistically significant (all <i>P</i><0.01). (2) Among the 15 960 singleton live birth FET patients, 926 (5.80%) were in underweight group, 10 620 (66.54%) were in normal weight group, 3 561 (22.31%) were in overweight group, and 853 (5.34%) were in obesity group. The incidences of preterm birth, extremely preterm birth, macrosomia and large for gestational age (LGA) in the overweight and obese groups were significantly higher than those in the normal weight group (all <i>P</i><0.05). The incidence of small for gestational age (SGA) infants in the underweight group was significantly higher than that in the normal weight group, while the incidences of preterm birth, macrosomia and LGA infants were all significantly lower than those in the normal weight group (all <i>P</i><0.05). (3) Maternal pre-pregnancy overweight and obesity were associated with early miscarriage (a<i>OR</i>=1.20, 1.37), preterm birth (a<i>OR</i>=1.49, 1.70), very preterm birth (a<i>OR</i>=1.64, 2.09), macrosomia (a<i>OR</i>=1.87, 2.57), and LGA (a<i>OR</i>=1.55, 1.95), and the risks of live birth (a<i>OR</i>=0.87, 0.80) and low birth weight infant (a<i>OR</i>=0.65, 0.51) were significantly decreased (all <i>P</i><0.01). Maternal pre-pregnancy underweight had no significant effect on early miscarriage, clinical pregnancy and live birth (all <i>P</
目的:探讨冻融胚胎移植(FET)周期中孕妇孕前体重指数(BMI)与临床妊娠结局和单胎活产结局的关系。方法:回顾性分析2013年1月至2023年12月在河南省人民医院及郑州大学第二附属医院行FET的患者45 856例,其中单胎活产15 960例。根据女性BMI分为体重过轻组(BMI2)、正常体重组(BMI 18.5-2)、超重组(BMI 25.0-2)和肥胖组(BMI≥30.0 kg/m2)。采用多元线性模型和logistic回归模型评价孕妇孕前BMI对临床妊娠结局和单胎活产结局的影响。采用广义加性模型拟合孕妇孕前BMI与围产期结局的曲线,确定阈值。结果:(1)45 856例FET患者中,体重过轻组2 390例(5.21%),正常体重组30 177例(65.81%),超重组10 835例(23.63%),肥胖组2 454例(5.35%)。超重、肥胖组的早期流产率、体重不足组的临床妊娠率、活产率、肥胖组的临床妊娠率均高于正常体重组,超重组的活产率均低于正常体重组,差异均有统计学意义(PPPOR均为1.20、1.37)、早产(aOR=1.49、1.70)、极早产(aOR=1.64、2.09)、巨大儿(aOR=1.87、2.57)、LGA (aOR=1.55、1.95),活产(aOR=0.87, 0.80)和低出生体重儿(aOR=0.65, 0.51)的风险显著降低(所有PP均为0.05),但早产(aOR=0.69)、巨大儿(aOR=0.34)和胎龄大(aOR=0.54)的风险显著降低;POR=1.09, 95%CI: 1.05 ~ 1.13; POR=0.93, 95%CI: 0.90 ~ 0.96;结论:孕前母亲超重和肥胖可增加FET中早流产率,降低活产率,增加单胎活产儿早产、极早产、巨大儿和LGA的风险。孕前BMI≤25.0 kg/m2的妇女围产期结局较好。
{"title":"[Association between maternal pre-pregnancy body mass index and clinical pregnancy outcomes and perinatal outcomes of single live birth in frozen-thawed embryo transfer cycles].","authors":"H Y Hao, Y G Xiang, X J Geng, N Jia, C L Zhang, M Li, S D Zhang","doi":"10.3760/cma.j.cn112141-20250423-00163","DOIUrl":"https://doi.org/10.3760/cma.j.cn112141-20250423-00163","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To investigate the relationship between maternal pre-pregnancy body mass index (BMI) and clinical pregnancy outcomes and singleton live birth outcomes in frozen-thawed embryo transfer (FET) cycles. &lt;b&gt;Methods:&lt;/b&gt; A total of 45 856 patients who underwent FET in Henan Provincial People's Hospital and the Second Affiliated Hospital of Zhengzhou University from January 2013 to December 2023 were retrospectively analyzed, including 15 960 singleton live births. Based on the female's BMI, they were divided into the underweight group (BMI&lt;18.5 kg/m&lt;sup&gt;2&lt;/sup&gt;), the normal weight group (BMI 18.5-&lt;25.0 kg/m&lt;sup&gt;2&lt;/sup&gt;), the overweight group (BMI 25.0-&lt;30.0 kg/m&lt;sup&gt;2&lt;/sup&gt;), and the obese group (BMI≥30.0 kg/m&lt;sup&gt;2&lt;/sup&gt;). Multivariate linear models and logistic regression models were used to evaluate the effects of maternal pre-pregnancy BMI on clinical pregnancy outcomes and singleton live birth outcomes. Generalized additive model was used to fit the curve between maternal pre-pregnancy BMI and perinatal outcomes and to determine the threshold. &lt;b&gt;Results:&lt;/b&gt; (1) Among 45 856 FET patients, there were 2 390 cases (5.21%) in the underweight group, 30 177 cases (65.81%) in the normal weight group, 10 835 cases (23.63%) in the overweight group, and 2 454 cases (5.35%) in the obesity group. The early abortion rate of overweight and obesity group, the clinical pregnancy rate and live birth rate of underweight group, the clinical pregnancy rate of obesity group were higher than those of normal weight group, and the live birth rate of overweight group was lower than that of normal weight group, and the differences were statistically significant (all &lt;i&gt;P&lt;/i&gt;&lt;0.01). (2) Among the 15 960 singleton live birth FET patients, 926 (5.80%) were in underweight group, 10 620 (66.54%) were in normal weight group, 3 561 (22.31%) were in overweight group, and 853 (5.34%) were in obesity group. The incidences of preterm birth, extremely preterm birth, macrosomia and large for gestational age (LGA) in the overweight and obese groups were significantly higher than those in the normal weight group (all &lt;i&gt;P&lt;/i&gt;&lt;0.05). The incidence of small for gestational age (SGA) infants in the underweight group was significantly higher than that in the normal weight group, while the incidences of preterm birth, macrosomia and LGA infants were all significantly lower than those in the normal weight group (all &lt;i&gt;P&lt;/i&gt;&lt;0.05). (3) Maternal pre-pregnancy overweight and obesity were associated with early miscarriage (a&lt;i&gt;OR&lt;/i&gt;=1.20, 1.37), preterm birth (a&lt;i&gt;OR&lt;/i&gt;=1.49, 1.70), very preterm birth (a&lt;i&gt;OR&lt;/i&gt;=1.64, 2.09), macrosomia (a&lt;i&gt;OR&lt;/i&gt;=1.87, 2.57), and LGA (a&lt;i&gt;OR&lt;/i&gt;=1.55, 1.95), and the risks of live birth (a&lt;i&gt;OR&lt;/i&gt;=0.87, 0.80) and low birth weight infant (a&lt;i&gt;OR&lt;/i&gt;=0.65, 0.51) were significantly decreased (all &lt;i&gt;P&lt;/i&gt;&lt;0.01). Maternal pre-pregnancy underweight had no significant effect on early miscarriage, clinical pregnancy and live birth (all &lt;i&gt;P&lt;/","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"61 1","pages":"39-49"},"PeriodicalIF":0.0,"publicationDate":"2026-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146084416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Value of self-sampling cervical exfoliated cells of HPV E6/E7 mRNA detection in cervical cancer screening: a multicenter clinical study]. [自取样宫颈脱落细胞检测HPV E6/E7 mRNA在宫颈癌筛查中的价值:一项多中心临床研究]。
Pub Date : 2026-01-25 DOI: 10.3760/cma.j.cn112141-20250909-00420
F Y Xiao, R C Ma, Y X Wang, J W Zhou, J W Li, L Sui

Objective: To evaluate the clinical value of self-sampling cervical exfoliated cells of HPV E6/E7 mRNA detection in cervical cancer screening. Methods: A total of 778 participants from Obstetrics and Gynecology Hospital of Fudan University, the Second Affiliated Hospital of Zhejiang University School of Medicine, Lianyungang Maternity and Child Health Hospital of Jiangsu Province, Yancheng Maternity and Child Health Hospital of Jiangsu Province and Yangzhou Maternity and Child Health Hospital of Jiangsu Province who were volunteered to engage in the study of self-sampling cervical exfoliated cells of HPV E6/E7 mRNA detection were included from March 2023 to April 2024. Both self-collected and clinician-collected samples underwent HPV E6/E7 mRNA detection. Statistical analysis was performed to compare the detection consistency between the two methods, and a questionnaire survey was used to assess participants' acceptance of self-sampling. Results: Among 778 participants, the sensitivity between self-collected and clinician-collected samples was 90.8%, specificity was 97.8%, and the overall agreement rate was 96.5%. The Kappa value was 0.883 (P<0.001), indicating high consistency between the two methods. Stratified analysis revealed that Kappa value>0.8, overall agreement >95.0% in different age groups and geographical regions. The questionnaire showed that 95.9% of participants preferred self-sampling, citing ease of use (43.6%), convenience (40.6%), and privacy (30.5%) as primary reasons. Additionally, 64.3% participants favored hospitals as the preferred location for self-sampling. Conclusion: Self-sampling demonstrates high consistency with clinician sampling for HPV E6/E7 mRNA testing and excellent acceptance, suggesting its potential as an effective tool to improve the coverage of cervical cancer screening.

目的:探讨自取样宫颈脱落细胞检测HPV E6/E7 mRNA在宫颈癌筛查中的临床价值。方法:来自复旦大学妇产科医院、浙江大学医学院第二附属医院、江苏省连云港市妇幼保健院、入选于2023年3月至2024年4月自愿参与自取样宫颈脱落细胞HPV E6/E7 mRNA检测研究的江苏省盐城妇幼保健院和江苏省扬州市妇幼保健院。自行采集和临床采集的样本均进行HPV E6/E7 mRNA检测。通过统计分析比较两种方法的检测一致性,并采用问卷调查的方式评估参与者对自抽样的接受程度。结果:778名受试者中,自行采集与临床采集标本的敏感性为90.8%,特异性为97.8%,总体符合率为96.5%。Kappa值为0.883 (P0.8),在不同年龄组和不同地理区域的总体一致性为95.0%。问卷显示,95.9%的参与者更倾向于自抽样,其中使用方便(43.6%)、方便(40.6%)和隐私(30.5%)是主要原因。此外,64.3%的受访者认为医院是自我抽样的首选地点。结论:自采样与临床采集的HPV E6/E7 mRNA检测结果一致性高,可接受性好,有望成为提高宫颈癌筛查覆盖率的有效工具。
{"title":"[Value of self-sampling cervical exfoliated cells of HPV E6/E7 mRNA detection in cervical cancer screening: a multicenter clinical study].","authors":"F Y Xiao, R C Ma, Y X Wang, J W Zhou, J W Li, L Sui","doi":"10.3760/cma.j.cn112141-20250909-00420","DOIUrl":"https://doi.org/10.3760/cma.j.cn112141-20250909-00420","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the clinical value of self-sampling cervical exfoliated cells of HPV E6/E7 mRNA detection in cervical cancer screening. <b>Methods:</b> A total of 778 participants from Obstetrics and Gynecology Hospital of Fudan University, the Second Affiliated Hospital of Zhejiang University School of Medicine, Lianyungang Maternity and Child Health Hospital of Jiangsu Province, Yancheng Maternity and Child Health Hospital of Jiangsu Province and Yangzhou Maternity and Child Health Hospital of Jiangsu Province who were volunteered to engage in the study of self-sampling cervical exfoliated cells of HPV E6/E7 mRNA detection were included from March 2023 to April 2024. Both self-collected and clinician-collected samples underwent HPV E6/E7 mRNA detection. Statistical analysis was performed to compare the detection consistency between the two methods, and a questionnaire survey was used to assess participants' acceptance of self-sampling. <b>Results:</b> Among 778 participants, the sensitivity between self-collected and clinician-collected samples was 90.8%, specificity was 97.8%, and the overall agreement rate was 96.5%. The Kappa value was 0.883 (<i>P</i><0.001), indicating high consistency between the two methods. Stratified analysis revealed that Kappa value>0.8, overall agreement >95.0% in different age groups and geographical regions. The questionnaire showed that 95.9% of participants preferred self-sampling, citing ease of use (43.6%), convenience (40.6%), and privacy (30.5%) as primary reasons. Additionally, 64.3% participants favored hospitals as the preferred location for self-sampling. <b>Conclusion:</b> Self-sampling demonstrates high consistency with clinician sampling for HPV E6/E7 mRNA testing and excellent acceptance, suggesting its potential as an effective tool to improve the coverage of cervical cancer screening.</p>","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"61 1","pages":"60-66"},"PeriodicalIF":0.0,"publicationDate":"2026-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146084411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Comparative analysis of clinicopathological and molecular characteristics between pure ovarian endometrioid carcinoma and synchronous endometrial and ovarian endometrioid carcinoma]. 【单纯卵巢子宫内膜样癌与同步子宫内膜及卵巢子宫内膜样癌的临床病理及分子特征比较分析】。
Pub Date : 2026-01-25 DOI: 10.3760/cma.j.cn112141-20250721-00330
C Wang, X Y Zhao, Y Liu, Y X Wang, J Yang, Z X Song, C R Liu
<p><p><b>Objective:</b> To investigate the differences in clinicopathological and molecular characteristics between pure ovarian endometrioid carcinoma (POEC) and synchronous endometrial and ovarian endometrioid carcinoma (SEOEC), aiming to provide a basis for their differential diagnosis and individualized treatment. <b>Methods:</b> Clinical and pathological data were collected from ovarian endometrioid carcinoma patients and they were divided into POEC group (219 cases) and SEOEC group (169 cases) according to whether they had endometrioid endometrial carcinoma or not. Clinical data including the age at onset, reasons for medical consultation, maximum diameter of ovarian tumors and pathological examination results such as histologic grading of the lesions were collected. Additionally, follow-up outcomes and survival status of the patients were also recorded. Molecular subtyping results were obtained from 108 cases of POEC group and 109 cases of SEOEC group patients. Large-scale targeted sequencing using next-generation sequencing was performed on 76 POEC group samples (32 with matched peripheral blood) and 51 SEOEC group samples (46 with matched peripheral blood/normal tissue). The prognosis of POEC group and SEOEC group were analyzed. Moreover, SEOEC group were further stratified to high-risk group and low-risk group according to 2020 WHO classification of tumors and 2023 International Federation of Gynecology and Obstetrics (FIGO) staging of endometrial cancer. <b>Results:</b> (1) Clinicopathological characteristics: compared to the SEOEC group, POEC group patients exhibited the following characteristics: younger age at diagnosis (50.0 years <i>vs</i> 38.0 years, <i>P</i><0.001), higher proportion presenting with typical ovarian cancer symptoms (45.7% <i>vs</i> 92.1%, <i>P</i><0.001), higher detection rates of ovarian endometriosis (14.9% <i>vs</i> 56.2%, <i>P</i><0.001) and uterine adenomyosis (23.0% <i>vs</i> 37.0%, <i>P</i>=0.021), higher proportion of low grade tumors (78.7% <i>vs</i> 95.4%, <i>P</i><0.001), lower proportion of mismatch repair deficiency subtype (23.9% <i>vs</i> 3.7%, <i>P</i><0.001). (2) Gene mutation profile: although the driver gene mutation profiles were similar between the two groups, POEC group patients had a significantly lower PTEN (22.4% <i>vs</i> 64.0%, <i>P</i><0.001) and CTNNB1 (22.4% <i>vs</i> 48.0%, <i>P</i>=0.014) mutation rates compared to SEOEC group. Also, POEC group had a higher KRAS mutation rate than SEOEC group patients (50.0% <i>vs</i> 28.0%, <i>P</i>=0.055). (3)Prognosis: survival analysis revealed that POEC group patients had a significantly shater progression free survival time compared to the low-risk SEOEC group patients(<i>P</i>=0.046). However, their long-term survival outcomes (both overall survival and disease specific survival) were significantly better than those of the high-risk SEOEC group patients (<i>P</i>=0.018 and <i>P</i>=0.046, respectively). <b>Conclusions:</b> POEC and SEOEC rep
目的:探讨纯卵巢子宫内膜样癌(POEC)与同步子宫内膜及卵巢子宫内膜样癌(SEOEC)的临床病理及分子特征差异,为其鉴别诊断及个体化治疗提供依据。方法:收集卵巢子宫内膜样癌患者的临床及病理资料,根据是否发生子宫内膜样癌分为POEC组(219例)和SEOEC组(169例)。收集发病年龄、就诊原因、卵巢肿瘤最大直径及病变组织学分级等病理检查结果等临床资料。此外,还记录了患者的随访结果和生存状况。对108例POEC组和109例SEOEC组患者进行分子分型。采用新一代测序技术对76例POEC组样本(32例外周血匹配)和51例SEOEC组样本(46例外周血/正常组织匹配)进行大规模靶向测序。分析POEC组和SEOEC组的预后。根据2020年WHO肿瘤分级和2023年国际妇产科学联合会(FIGO)子宫内膜癌分期,将SEOEC组进一步分为高危组和低危组。结果:(1)临床病理特征:与SEOEC组相比,POEC组患者表现出以下特点:诊断年龄更年轻(50.0岁vs 38.0岁,Pvs 92.1%, Pvs 56.2%, Pvs 37.0%, P=0.021),低级别肿瘤比例更高(78.7% vs 95.4%, Pvs 3.7%, Pvs 64.0%, Pvs 48.0%, P=0.014)突变率。POEC组KRAS突变率高于SEOEC组(50.0% vs 28.0%, P=0.055)。(3)预后:生存分析显示POEC组患者的无进展生存时间明显短于低危SEOEC组患者(P=0.046)。然而,他们的长期生存结局(总生存期和疾病特异性生存期)明显优于高危SEOEC组患者(P=0.018和P=0.046)。结论:POEC和SEOEC是两种不同的肿瘤实体,具有明显不同的临床、病理和分子特征。准确的鉴别诊断对正确的临床决策至关重要。
{"title":"[Comparative analysis of clinicopathological and molecular characteristics between pure ovarian endometrioid carcinoma and synchronous endometrial and ovarian endometrioid carcinoma].","authors":"C Wang, X Y Zhao, Y Liu, Y X Wang, J Yang, Z X Song, C R Liu","doi":"10.3760/cma.j.cn112141-20250721-00330","DOIUrl":"https://doi.org/10.3760/cma.j.cn112141-20250721-00330","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To investigate the differences in clinicopathological and molecular characteristics between pure ovarian endometrioid carcinoma (POEC) and synchronous endometrial and ovarian endometrioid carcinoma (SEOEC), aiming to provide a basis for their differential diagnosis and individualized treatment. &lt;b&gt;Methods:&lt;/b&gt; Clinical and pathological data were collected from ovarian endometrioid carcinoma patients and they were divided into POEC group (219 cases) and SEOEC group (169 cases) according to whether they had endometrioid endometrial carcinoma or not. Clinical data including the age at onset, reasons for medical consultation, maximum diameter of ovarian tumors and pathological examination results such as histologic grading of the lesions were collected. Additionally, follow-up outcomes and survival status of the patients were also recorded. Molecular subtyping results were obtained from 108 cases of POEC group and 109 cases of SEOEC group patients. Large-scale targeted sequencing using next-generation sequencing was performed on 76 POEC group samples (32 with matched peripheral blood) and 51 SEOEC group samples (46 with matched peripheral blood/normal tissue). The prognosis of POEC group and SEOEC group were analyzed. Moreover, SEOEC group were further stratified to high-risk group and low-risk group according to 2020 WHO classification of tumors and 2023 International Federation of Gynecology and Obstetrics (FIGO) staging of endometrial cancer. &lt;b&gt;Results:&lt;/b&gt; (1) Clinicopathological characteristics: compared to the SEOEC group, POEC group patients exhibited the following characteristics: younger age at diagnosis (50.0 years &lt;i&gt;vs&lt;/i&gt; 38.0 years, &lt;i&gt;P&lt;/i&gt;&lt;0.001), higher proportion presenting with typical ovarian cancer symptoms (45.7% &lt;i&gt;vs&lt;/i&gt; 92.1%, &lt;i&gt;P&lt;/i&gt;&lt;0.001), higher detection rates of ovarian endometriosis (14.9% &lt;i&gt;vs&lt;/i&gt; 56.2%, &lt;i&gt;P&lt;/i&gt;&lt;0.001) and uterine adenomyosis (23.0% &lt;i&gt;vs&lt;/i&gt; 37.0%, &lt;i&gt;P&lt;/i&gt;=0.021), higher proportion of low grade tumors (78.7% &lt;i&gt;vs&lt;/i&gt; 95.4%, &lt;i&gt;P&lt;/i&gt;&lt;0.001), lower proportion of mismatch repair deficiency subtype (23.9% &lt;i&gt;vs&lt;/i&gt; 3.7%, &lt;i&gt;P&lt;/i&gt;&lt;0.001). (2) Gene mutation profile: although the driver gene mutation profiles were similar between the two groups, POEC group patients had a significantly lower PTEN (22.4% &lt;i&gt;vs&lt;/i&gt; 64.0%, &lt;i&gt;P&lt;/i&gt;&lt;0.001) and CTNNB1 (22.4% &lt;i&gt;vs&lt;/i&gt; 48.0%, &lt;i&gt;P&lt;/i&gt;=0.014) mutation rates compared to SEOEC group. Also, POEC group had a higher KRAS mutation rate than SEOEC group patients (50.0% &lt;i&gt;vs&lt;/i&gt; 28.0%, &lt;i&gt;P&lt;/i&gt;=0.055). (3)Prognosis: survival analysis revealed that POEC group patients had a significantly shater progression free survival time compared to the low-risk SEOEC group patients(&lt;i&gt;P&lt;/i&gt;=0.046). However, their long-term survival outcomes (both overall survival and disease specific survival) were significantly better than those of the high-risk SEOEC group patients (&lt;i&gt;P&lt;/i&gt;=0.018 and &lt;i&gt;P&lt;/i&gt;=0.046, respectively). &lt;b&gt;Conclusions:&lt;/b&gt; POEC and SEOEC rep","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"61 1","pages":"50-59"},"PeriodicalIF":0.0,"publicationDate":"2026-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146084469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Detection of fetal cardiac dysgenesis by SNP array technology and the variation hotspots of the local population]. 【SNP阵列技术检测胎儿心脏发育不良及当地人群变异热点】。
Pub Date : 2026-01-25 DOI: 10.3760/cma.j.cn112141-20250627-00301
L Ma, X Yang, R M Liu, H Wu, J Liu, C M Sun
<p><p><b>Objective:</b> To investigate the application of single nucleotide polymorphism array (SNP array) in the detection of fetal cardiac dysplasia and to explore the characteristics of chromosomal variants associated with fetal cardiac dysplasia in the local population. <b>Methods:</b> A total of 556 pregnant women who underwent SNP array examination in Yantai Yuhuangding Hospital Affiliated to Medical College of Qingdao University from January 2021 to December 2024 because of abnormal soft index or structural malformations of fetal heart development by ultrasound examination were collected. According to the results of fetal ultrasound examination, they were divided into single abnormal soft markers group (237 cases), multiple abnormal soft index group (232 cases), soft index combined with cardiac structural abnormalities group (24 cases), isolated cardiac structural abnormalities group (47 cases), and cardiac structural abnormalities combined with other systemic abnormalities group (16 cases). According to the age of pregnant women, they were divided into ≤25 years old group (20 cases), 26-29 years old group (155 cases), 30-34 years old group (190 cases), 35-39 years old group (149 cases) and ≥40 years old group (42 cases). The differences in the detection of chromosomal abnormalities in pregnant women with different echocardiographic results and different ages were compared. <b>Results:</b> (1) Among the 556 pregnant women who underwent SNP array for fetal cardiac anomalies, 110 cases of fetal chromosomal variations were detected, with a detection rate of 19.8% (110/556), including 72 cases of pathogenic variations (12.9%, 72/556) and 38 cases of variants of uncertain significance (VUS; 6.8%, 38/556). Pathogenic copy number variations (CNV) involved 9 chromosomes, with 3q29, 16p13.11, 17p13.3p13.2 and 22q11.21 being the most common. (2) Among the pregnant women with different ultrasound results, the highest detection rate of fetal chromosomal variation was in the group with cardiac structural abnormalities combined with other systemic abnormalities, with a detection rate of 10/16. The detection rates of single abnormal soft index group, multiple abnormal soft index group, soft index combined with cardiac structural abnormalities group and isolated cardiac structural abnormalities group were 17.3% (41/237), 18.1% (42/232), 41.7% (10/24) and 14.9% (7/47), respectively, and the differences were statistically significant (<i>χ</i><sup>2</sup>=27.680, <i>P</i><0.001). (3) In different age groups, the detection rate of chromosome aneuploidy increased with age, and the detection rate of ≥40 years old group (16.7%, 7/42) was the highest. There was no significant difference in the detection rate of pathogenic CNV, VUS and chromosomal abnormalities among different age groups (all <i>P</i>>0.05). <b>Conclusions:</b> SNP array technology has important application value in prenatal diagnosis of fetal cardiac anomalies. The study on the characteristics o
目的:探讨单核苷酸多态性阵列(SNP阵列)在胎儿心脏发育不良检测中的应用,探讨当地人群胎儿心脏发育不良相关染色体变异的特点。方法:收集2021年1月至2024年12月在青岛大学医学院附属烟台玉皇顶医院因超声检查发现胎儿心脏发育软指标异常或结构畸形而行SNP阵列检查的孕妇556例。根据胎儿超声检查结果分为单个软指标异常组237例、多个软指标异常组232例、软指标合并心脏结构异常组24例、孤立性心脏结构异常组47例、心脏结构异常合并其他全身异常组16例。根据孕妇年龄分为≤25岁组(20例)、26-29岁组(155例)、30-34岁组(190例)、35-39岁组(149例)、≥40岁组(42例)。比较不同超声心动图结果及不同年龄孕妇染色体异常检出率的差异。结果:(1)556例孕妇行胎儿心脏异常SNP测序,共检出胎儿染色体变异110例,检出率为19.8%(110/556),其中病原变异72例(12.9%,72/556),意义不确定变异38例(VUS; 6.8%, 38/556)。致病性拷贝数变异(CNV)涉及9条染色体,以3q29、16p13.11、17p13.3p13.2和22q11.21最为常见。(2)在不同超声结果的孕妇中,胎儿染色体变异检出率最高的是心脏结构异常合并其他全身异常组,检出率为10/16。单个软指标异常组、多个软指标异常组、软指标合并心脏结构异常组、单独心脏结构异常组的检出率分别为17.3%(41/237)、18.1%(42/232)、41.7%(10/24)、14.9%(7/47),差异均有统计学意义(χ2=27.680, PP>0.05)。结论:SNP阵列技术在胎儿心脏异常的产前诊断中具有重要的应用价值。研究当地人群与胎儿心脏异常相关的染色体变异特征,有利于先天性心脏病的精准治疗。
{"title":"[Detection of fetal cardiac dysgenesis by SNP array technology and the variation hotspots of the local population].","authors":"L Ma, X Yang, R M Liu, H Wu, J Liu, C M Sun","doi":"10.3760/cma.j.cn112141-20250627-00301","DOIUrl":"https://doi.org/10.3760/cma.j.cn112141-20250627-00301","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To investigate the application of single nucleotide polymorphism array (SNP array) in the detection of fetal cardiac dysplasia and to explore the characteristics of chromosomal variants associated with fetal cardiac dysplasia in the local population. &lt;b&gt;Methods:&lt;/b&gt; A total of 556 pregnant women who underwent SNP array examination in Yantai Yuhuangding Hospital Affiliated to Medical College of Qingdao University from January 2021 to December 2024 because of abnormal soft index or structural malformations of fetal heart development by ultrasound examination were collected. According to the results of fetal ultrasound examination, they were divided into single abnormal soft markers group (237 cases), multiple abnormal soft index group (232 cases), soft index combined with cardiac structural abnormalities group (24 cases), isolated cardiac structural abnormalities group (47 cases), and cardiac structural abnormalities combined with other systemic abnormalities group (16 cases). According to the age of pregnant women, they were divided into ≤25 years old group (20 cases), 26-29 years old group (155 cases), 30-34 years old group (190 cases), 35-39 years old group (149 cases) and ≥40 years old group (42 cases). The differences in the detection of chromosomal abnormalities in pregnant women with different echocardiographic results and different ages were compared. &lt;b&gt;Results:&lt;/b&gt; (1) Among the 556 pregnant women who underwent SNP array for fetal cardiac anomalies, 110 cases of fetal chromosomal variations were detected, with a detection rate of 19.8% (110/556), including 72 cases of pathogenic variations (12.9%, 72/556) and 38 cases of variants of uncertain significance (VUS; 6.8%, 38/556). Pathogenic copy number variations (CNV) involved 9 chromosomes, with 3q29, 16p13.11, 17p13.3p13.2 and 22q11.21 being the most common. (2) Among the pregnant women with different ultrasound results, the highest detection rate of fetal chromosomal variation was in the group with cardiac structural abnormalities combined with other systemic abnormalities, with a detection rate of 10/16. The detection rates of single abnormal soft index group, multiple abnormal soft index group, soft index combined with cardiac structural abnormalities group and isolated cardiac structural abnormalities group were 17.3% (41/237), 18.1% (42/232), 41.7% (10/24) and 14.9% (7/47), respectively, and the differences were statistically significant (&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=27.680, &lt;i&gt;P&lt;/i&gt;&lt;0.001). (3) In different age groups, the detection rate of chromosome aneuploidy increased with age, and the detection rate of ≥40 years old group (16.7%, 7/42) was the highest. There was no significant difference in the detection rate of pathogenic CNV, VUS and chromosomal abnormalities among different age groups (all &lt;i&gt;P&lt;/i&gt;&gt;0.05). &lt;b&gt;Conclusions:&lt;/b&gt; SNP array technology has important application value in prenatal diagnosis of fetal cardiac anomalies. The study on the characteristics o","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"61 1","pages":"23-29"},"PeriodicalIF":0.0,"publicationDate":"2026-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146084436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Efficacy and safety of triptorelin acetate microspheres for injection versus triptorelin acetate for injection in Chinese patients with endometriosis: a multicenter, randomized, double-blind, phase Ⅲ non-inferiority clinical trial]. [注射用醋酸雷普雷林微球与注射用醋酸雷普雷林治疗子宫内膜异位症的疗效和安全性:一项多中心、随机、双盲、Ⅲ期非劣效性临床试验]。
Pub Date : 2026-01-25 DOI: 10.3760/cma.j.cn112141-20250421-00161
A M Zhao, Y Wang, W W Yang, Z Q Liang, F J Shen, C Z Li, Z T Wei, X J Sheng, W Yuan, Q Li, F Ming, Y H Zheng, X Y Lu, H Ye, J J Li, B Lye, H J Ruan, Y Z Zhang, Y X Li, W R Li, H K Yang, Y L Zheng, X J Dong, H Lu, S Y Hou, P Yan, Y Q Ge, J L Kang, L N Wang, H Y Zhang, Y Hu, R F Zhao, Y L Wang, S Y Zhang, L P Han, L Sang, M H Cui, J J Zhai, D Lu, Y Zheng, Y Z Guo, M L Chen, L P Sun, J Lu, S J Guo, X H Zhang, W Feng, L H Yang
<p><p><b>Objective:</b> To evaluate the efficacy and safety of triptorelin acetate microspheres for injection compared with triptorelin acetate for injection in the treatment of endometriosis. <b>Methods:</b> A total of 392 patients with endometriosis were prospectively enrolled from 47 research centers across China between October 25, 2021, and February 14, 2023. Participants were randomly assigned in a 1∶1 ratio to either the experimental group (<i>n</i>=196) or the control group (<i>n</i>=196). Both groups received intramuscular injections of the respective drugs once every 4 weeks for a total of 6 doses. The primary efficacy endpoint was the percentage of subjects with suppressed estradiol levels after treatment. Secondary endpoints included pain relief, amenorrhea rate, changes in ovarian endometrioma diameter, and adverse drug reactions. <b>Results:</b> For the primary efficacy endpoint, the percentages of subjects with suppressed estradiol levels at week 12 in the experimental and control groups were 97.3% (177/182) and 98.4% (181/184), respectively. The rate difference was -1.1% (95%<i>CI</i>: -4.8% to 2.3%), the lower limit of the 95%<i>CI</i> for the rate difference was greater than the non-inferiority margin of -10%. Compared to baseline, visual analog scale (VAS) scores for dysmenorrhea and non-menstrual pelvic pain decreased at all post-treatment time points in both groups, with no statistically significant differences between two groups (all <i>P</i>>0.05). Estradiol, luteinizing hormone, and follicle stimulating hormone levels significantly decreased from baseline at all post-treatment time points in both groups (all <i>P</i><0.05), with no significant intergroup differences (all <i>P</i>>0.05). No significant differences were observed in amenorrhea rates between two groups at week 8, 12, and 24 post-treatment (all <i>P</i>>0.05). However, the time to menstruation recovery after drug discontinuation was significantly earlier in the experimental group than that in the control group (<i>P</i>=0.003). Carbohydrate antigen 125 levels significantly decreased from baseline at week 12 and 24 post-treatment in both groups (all <i>P</i><0.001), but no significant intergroup differences were found (all <i>P</i>>0.05). In the experimental group, only the diameter of the right ovarian endometrioma showed a significant decrease from baseline at week 24 post-treatment (<i>P</i>=0.016). In the control group, neither left nor right ovarian endometrioma diameters showed significant changes from baseline (all <i>P</i>>0.05). The overall incidence of adverse drug reactions was similar between the experimental and control groups [77.6% (152/196) vs 78.6% (154/196), respectively; <i>P</i>>0.05]. <b>Conclusions:</b> Triptorelin acetate microspheres for injection is an effective treatment for endometriosis. It could maintain low estrogen levels, consistently alleviate endometriosis-associated pain, achieve a high rate of amenorrhea during treatment, and
目的:比较注射用醋酸雷普雷林微球与注射用醋酸雷普雷林治疗子宫内膜异位症的疗效和安全性。方法:在2021年10月25日至2023年2月14日期间,来自中国47个研究中心的392名子宫内膜异位症患者被前瞻性纳入研究。受试者按1∶1的比例随机分为实验组(n=196)和对照组(n=196)。两组患者均肌肉注射相应药物,每4周1次,共6次。主要疗效终点是治疗后雌二醇水平被抑制的受试者百分比。次要终点包括疼痛缓解、闭经率、卵巢子宫内膜瘤直径变化和药物不良反应。结果:在主要疗效终点,实验组和对照组在第12周雌二醇水平被抑制的比例分别为97.3%(177/182)和98.4%(181/184)。差异率为-1.1% (95%CI: -4.8%至2.3%),差异率95%CI的下限大于-10%的非劣效性边际。与基线相比,两组痛经和非经期盆腔疼痛的视觉模拟评分(VAS)在治疗后各时间点均下降,两组间差异无统计学意义(均P < 0.05)。两组治疗后各时间点雌二醇、促黄体生成素和促卵泡激素水平均较基线显著降低(p < 0.05)。两组患者治疗后8周、12周、24周闭经率差异无统计学意义(P < 0.05)。但实验组停药后月经恢复时间明显早于对照组(P=0.003)。治疗后第12周和第24周,两组碳水化合物抗原125水平均较基线显著降低(p < 0.05)。实验组仅右侧卵巢子宫内膜瘤直径在治疗后第24周较基线有显著降低(P=0.016)。对照组左、右卵巢子宫内膜瘤直径较基线均无明显变化(P < 0.05)。试验组和对照组药物不良反应总发生率相似,分别为77.6%(152/196)和78.6% (154/196);P > 0.05)。结论:注射用醋酸雷普雷林微球是治疗子宫内膜异位症的有效药物。它可以维持低雌激素水平,持续缓解子宫内膜异位症相关疼痛,治疗期间闭经率高,并在一定程度上缩小卵巢子宫内膜异位症的大小,具有良好的安全性。
{"title":"[Efficacy and safety of triptorelin acetate microspheres for injection versus triptorelin acetate for injection in Chinese patients with endometriosis: a multicenter, randomized, double-blind, phase Ⅲ non-inferiority clinical trial].","authors":"A M Zhao, Y Wang, W W Yang, Z Q Liang, F J Shen, C Z Li, Z T Wei, X J Sheng, W Yuan, Q Li, F Ming, Y H Zheng, X Y Lu, H Ye, J J Li, B Lye, H J Ruan, Y Z Zhang, Y X Li, W R Li, H K Yang, Y L Zheng, X J Dong, H Lu, S Y Hou, P Yan, Y Q Ge, J L Kang, L N Wang, H Y Zhang, Y Hu, R F Zhao, Y L Wang, S Y Zhang, L P Han, L Sang, M H Cui, J J Zhai, D Lu, Y Zheng, Y Z Guo, M L Chen, L P Sun, J Lu, S J Guo, X H Zhang, W Feng, L H Yang","doi":"10.3760/cma.j.cn112141-20250421-00161","DOIUrl":"https://doi.org/10.3760/cma.j.cn112141-20250421-00161","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To evaluate the efficacy and safety of triptorelin acetate microspheres for injection compared with triptorelin acetate for injection in the treatment of endometriosis. &lt;b&gt;Methods:&lt;/b&gt; A total of 392 patients with endometriosis were prospectively enrolled from 47 research centers across China between October 25, 2021, and February 14, 2023. Participants were randomly assigned in a 1∶1 ratio to either the experimental group (&lt;i&gt;n&lt;/i&gt;=196) or the control group (&lt;i&gt;n&lt;/i&gt;=196). Both groups received intramuscular injections of the respective drugs once every 4 weeks for a total of 6 doses. The primary efficacy endpoint was the percentage of subjects with suppressed estradiol levels after treatment. Secondary endpoints included pain relief, amenorrhea rate, changes in ovarian endometrioma diameter, and adverse drug reactions. &lt;b&gt;Results:&lt;/b&gt; For the primary efficacy endpoint, the percentages of subjects with suppressed estradiol levels at week 12 in the experimental and control groups were 97.3% (177/182) and 98.4% (181/184), respectively. The rate difference was -1.1% (95%&lt;i&gt;CI&lt;/i&gt;: -4.8% to 2.3%), the lower limit of the 95%&lt;i&gt;CI&lt;/i&gt; for the rate difference was greater than the non-inferiority margin of -10%. Compared to baseline, visual analog scale (VAS) scores for dysmenorrhea and non-menstrual pelvic pain decreased at all post-treatment time points in both groups, with no statistically significant differences between two groups (all &lt;i&gt;P&lt;/i&gt;&gt;0.05). Estradiol, luteinizing hormone, and follicle stimulating hormone levels significantly decreased from baseline at all post-treatment time points in both groups (all &lt;i&gt;P&lt;/i&gt;&lt;0.05), with no significant intergroup differences (all &lt;i&gt;P&lt;/i&gt;&gt;0.05). No significant differences were observed in amenorrhea rates between two groups at week 8, 12, and 24 post-treatment (all &lt;i&gt;P&lt;/i&gt;&gt;0.05). However, the time to menstruation recovery after drug discontinuation was significantly earlier in the experimental group than that in the control group (&lt;i&gt;P&lt;/i&gt;=0.003). Carbohydrate antigen 125 levels significantly decreased from baseline at week 12 and 24 post-treatment in both groups (all &lt;i&gt;P&lt;/i&gt;&lt;0.001), but no significant intergroup differences were found (all &lt;i&gt;P&lt;/i&gt;&gt;0.05). In the experimental group, only the diameter of the right ovarian endometrioma showed a significant decrease from baseline at week 24 post-treatment (&lt;i&gt;P&lt;/i&gt;=0.016). In the control group, neither left nor right ovarian endometrioma diameters showed significant changes from baseline (all &lt;i&gt;P&lt;/i&gt;&gt;0.05). The overall incidence of adverse drug reactions was similar between the experimental and control groups [77.6% (152/196) vs 78.6% (154/196), respectively; &lt;i&gt;P&lt;/i&gt;&gt;0.05]. &lt;b&gt;Conclusions:&lt;/b&gt; Triptorelin acetate microspheres for injection is an effective treatment for endometriosis. It could maintain low estrogen levels, consistently alleviate endometriosis-associated pain, achieve a high rate of amenorrhea during treatment, and ","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"61 1","pages":"30-38"},"PeriodicalIF":0.0,"publicationDate":"2026-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146084400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Analysis of reproductive and psychological health of pregnant women with placenta accreta spectrum disorders after fertility-preserving treatment]. [保留生育能力治疗后胎盘增生谱系障碍孕妇生殖与心理健康分析]。
Pub Date : 2026-01-25 DOI: 10.3760/cma.j.cn112141-20250824-00395
W R Zheng, B E Huang, X R Yang, J Yan, H X Yang

Objective: To analyze the reproductive and psychological health status of pregnant women with placenta accreta spectrum disorders (PAS) after fertile-preserving surgery, and to follow up their subsequent pregnancy and delivery. Methods: A total of 269 cases of abnormally invasive placenta (AIP) who underwent pregnancy supervision and surgical treatment in Peking University First Hospital from January 2010 to August 2020 were collected as AIP group. A total of 300 pregnant women without other complications who underwent elective cesarean section due to cesarean section history in the same center and at the same time period were selected as the control group. Their clinical information was collected, and their menstruation, fertility and psychological health were followed up by telephone and online questionnaire. Results: (1) In AIP group, 222 (82.5%, 222/269) valid questionnaires were returned, of which 171 (77.0%, 171/222) completed the subjective scale. The control group returned 254 valid questionnaires (84.7%, 254/300), of which 191 (75.2%, 191/254) filled in the complete subjective scale. There was no significant difference in the demographic characteristics between AIP group and control group (all P>0.05), but the intraoperative blood loss, the incidence of short-term postoperative complications and the length of hospital stay in AIP group were higher than those in control group. (2) There were no differences in reproductive physiological health status, including the time to resume sexual life, menstruation, re-pregnancy, pelvic ultrasound manifestations and long-term complications between AIP group and control group. The fertility intention of AIP group was lower than that of control group [12.3% (25/204) vs 19.3% (49/254)]. (3) In AIP group, 17 women tried to get pregnant again, and 12 of them (12/17) had successful pregnancy and delivered, and no PAS occurred again. (4) FSFI scores of women undergoing hysterectomy (18 cases) were lower than those undergoing fertive-sparing surgery (204 cases) in AIP group, but there was no differences in the proportion of pelvic floor dysfunction and suspicious emotional disorder. Conclusions: The physiological function of pelvic organs in women with AIP can be restored after fertive-preserving surgery, which is similar to that of women with a history of cesarean section. The risk of pelvic floor dysfunction and emotional disorders is not significantly increased after hysterectomy, but the risk of sexual dysfunction is higher. Hysterectomy is not recommended as the first-line treatment for PAS. Women with fertility desire can get pregnant again and deliver by cesarean section, but PAS should be closely monitored for recurrence during pregnancy.

目的:分析保生育手术后胎盘增生谱系障碍(PAS)孕妇的生殖和心理健康状况,并对其妊娠和分娩情况进行随访。方法:收集2010年1月至2020年8月在北京大学第一医院接受妊娠监护和手术治疗的269例异常浸润性胎盘(AIP)作为AIP组。选取同一中心同一时间段有剖宫产史且无其他并发症的孕妇300例作为对照组。收集她们的临床资料,并通过电话和网络问卷对她们的月经、生育和心理健康状况进行随访。结果:(1)AIP组共回收有效问卷222份(82.5%,222/269),其中完成主观量表171份(77.0%,171/222)。对照组共返回有效问卷254份(84.7%,254/300),其中191份(75.2%,191/254)填写了完整的主观量表。AIP组与对照组人口学特征比较差异无统计学意义(P < 0.05),但AIP组术中出血量、术后短期并发症发生率、住院时间均高于对照组。(2) AIP组与对照组在恢复性生活时间、月经、再妊娠、盆腔超声表现、长期并发症等生殖生理健康状况上无差异。AIP组生育意愿低于对照组[12.3% (25/204)vs 19.3%(49/254)]。(3) AIP组有17例再次尝试怀孕,其中12例(12/17)成功怀孕并分娩,未再次发生PAS。(4) AIP组子宫切除术妇女FSFI评分(18例)低于保孕手术妇女(204例),但盆底功能障碍和可疑情绪障碍的比例无差异。结论:保育手术后AIP患者盆腔器官的生理功能恢复与有剖宫产史的女性相似。子宫切除术后盆底功能障碍和情绪障碍的风险没有明显增加,但性功能障碍的风险更高。子宫切除术不推荐作为PAS的一线治疗。有生育愿望的妇女可以再次怀孕,通过剖宫产分娩,但在怀孕期间应密切监测PAS复发。
{"title":"[Analysis of reproductive and psychological health of pregnant women with placenta accreta spectrum disorders after fertility-preserving treatment].","authors":"W R Zheng, B E Huang, X R Yang, J Yan, H X Yang","doi":"10.3760/cma.j.cn112141-20250824-00395","DOIUrl":"https://doi.org/10.3760/cma.j.cn112141-20250824-00395","url":null,"abstract":"<p><p><b>Objective:</b> To analyze the reproductive and psychological health status of pregnant women with placenta accreta spectrum disorders (PAS) after fertile-preserving surgery, and to follow up their subsequent pregnancy and delivery. <b>Methods:</b> A total of 269 cases of abnormally invasive placenta (AIP) who underwent pregnancy supervision and surgical treatment in Peking University First Hospital from January 2010 to August 2020 were collected as AIP group. A total of 300 pregnant women without other complications who underwent elective cesarean section due to cesarean section history in the same center and at the same time period were selected as the control group. Their clinical information was collected, and their menstruation, fertility and psychological health were followed up by telephone and online questionnaire. <b>Results:</b> (1) In AIP group, 222 (82.5%, 222/269) valid questionnaires were returned, of which 171 (77.0%, 171/222) completed the subjective scale. The control group returned 254 valid questionnaires (84.7%, 254/300), of which 191 (75.2%, 191/254) filled in the complete subjective scale. There was no significant difference in the demographic characteristics between AIP group and control group (all <i>P</i>>0.05), but the intraoperative blood loss, the incidence of short-term postoperative complications and the length of hospital stay in AIP group were higher than those in control group. (2) There were no differences in reproductive physiological health status, including the time to resume sexual life, menstruation, re-pregnancy, pelvic ultrasound manifestations and long-term complications between AIP group and control group. The fertility intention of AIP group was lower than that of control group [12.3% (25/204) vs 19.3% (49/254)]. (3) In AIP group, 17 women tried to get pregnant again, and 12 of them (12/17) had successful pregnancy and delivered, and no PAS occurred again. (4) FSFI scores of women undergoing hysterectomy (18 cases) were lower than those undergoing fertive-sparing surgery (204 cases) in AIP group, but there was no differences in the proportion of pelvic floor dysfunction and suspicious emotional disorder. <b>Conclusions:</b> The physiological function of pelvic organs in women with AIP can be restored after fertive-preserving surgery, which is similar to that of women with a history of cesarean section. The risk of pelvic floor dysfunction and emotional disorders is not significantly increased after hysterectomy, but the risk of sexual dysfunction is higher. Hysterectomy is not recommended as the first-line treatment for PAS. Women with fertility desire can get pregnant again and deliver by cesarean section, but PAS should be closely monitored for recurrence during pregnancy.</p>","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"61 1","pages":"16-22"},"PeriodicalIF":0.0,"publicationDate":"2026-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146084438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical analysis of 12 cases of pregnancy complicated with diffuse uterine leiomyomatosis]. 妊娠合并弥漫性子宫平滑肌瘤病12例临床分析
Pub Date : 2025-12-25 DOI: 10.3760/cma.j.cn112141-20250705-00310
W L Han, L Chen

Objective: To analyze the clinical characteristics, diagnosis and treatment of pregnancy complicated with diffuse uterine leiomyomatosis (DUL), and to explore the treatment strategies for its complications during pregnancy and perinatal period. Methods: The clinical data of 12 pregnant women with DUL who delivered in Peking University Third Hospital from May 2017 to October 2024 were collected, and their complications during pregnancy and perinatal period, radiological features, and treatment strategies were analyzed. Results: The median age of 12 pregnant women with DUL was 32 years (range: 28 to 38 years), and all of them were primiparas with singleton pregnancy. Among the 12 pregnant women, only 7 cases (7/12) were suspected of DUL by imaging examination during pregnancy. Five cases (5/12) only showed multiple uterine fibroids by ultrasound and magnetic resonance imaging during pregnancy, which were finally diagnosed according to intraoperative exploration. Five cases (5/12) of DUL had signs of threatened abortion or threatened preterm birth such as uterine contraction and bleeding during pregnancy, including 3 cases of preterm birth (2 cases of spontaneous preterm birth and 1 case of iatrogenic preterm birth due to prenatal hemorrhage). Among the 12 pregnant women with DUL, 2 cases (2/12) had abnormal fetal position, 3 cases (3/12) had placental adhesion, and 1 case (1/12) had fibroid degeneration. Among the 12 pregnant women with DUL, 9 cases (9/12) were delivered by cesarean section, of which 3 cases were converted to cesarean section because of failed trial of labor, and 6 cases were directly terminated by cesarean section because of abnormal fetal position or previous myomectomy history. Postpartum hemorrhage occurred in 5 cases (5/12), including 4 cases of severe postpartum hemorrhage, and uterine tamponade had good hemostatic effect. Three cases (3/12) had fever after operation or postpartum. All the 12 pregnant women were discharged in a stable condition. Among the 12 neonates, 2 (2/12) were transferred to the department of pediatrics due to premature birth and finally discharged smoothly. Conclusions: Pregnancy complicated with DUL is a high-risk pregnancy, which increases the risk of complications during gestation, delivery and postpartum. Uterine cavity compression hemostasis may be an effective measure to deal with postpartum hemorrhage.

目的:分析妊娠合并弥漫性子宫平滑肌瘤病(DUL)的临床特点、诊断及治疗,探讨其妊娠期及围生期并发症的治疗策略。方法:收集2017年5月至2024年10月在北京大学第三医院分娩的12例DUL孕妇的临床资料,分析其妊娠及围产期并发症、影像学特征及治疗策略。结果:12例妊娠DUL患者中位年龄32岁(范围28 ~ 38岁),均为初产妇单胎妊娠。12例孕妇中,仅有7例(7/12)在孕期影像学检查中怀疑为DUL。5例(5/12)在妊娠期仅通过超声和磁共振成像显示多发性子宫肌瘤,最终通过术中探查诊断。5例(5/12)DUL患者在妊娠期间出现子宫收缩、出血等先兆流产或先兆早产体征,其中早产3例(自发性早产2例,产前出血所致医源性早产1例)。12例妊娠DUL患者中,2例(2/12)胎儿位置异常,3例(3/12)胎盘粘连,1例(1/12)子宫肌瘤变性。12例妊娠DUL患者中,9例(9/12)采用剖宫产分娩,其中3例因试产失败转行剖宫产,6例因胎位异常或既往子宫肌瘤切除史直接终止剖宫产。产后出血5例(5/12),其中重度产后出血4例,子宫填塞止血效果良好。术后或产后发热3例(3/12)。12名孕妇出院时情况稳定。12例新生儿中,2例(2/12)因早产转至儿科,最终顺利出院。结论:妊娠合并DUL是高危妊娠,妊娠、分娩及产后并发症的发生风险增加。子宫腔压迫止血可能是治疗产后出血的有效措施。
{"title":"[Clinical analysis of 12 cases of pregnancy complicated with diffuse uterine leiomyomatosis].","authors":"W L Han, L Chen","doi":"10.3760/cma.j.cn112141-20250705-00310","DOIUrl":"https://doi.org/10.3760/cma.j.cn112141-20250705-00310","url":null,"abstract":"<p><p><b>Objective:</b> To analyze the clinical characteristics, diagnosis and treatment of pregnancy complicated with diffuse uterine leiomyomatosis (DUL), and to explore the treatment strategies for its complications during pregnancy and perinatal period. <b>Methods:</b> The clinical data of 12 pregnant women with DUL who delivered in Peking University Third Hospital from May 2017 to October 2024 were collected, and their complications during pregnancy and perinatal period, radiological features, and treatment strategies were analyzed. <b>Results:</b> The median age of 12 pregnant women with DUL was 32 years (range: 28 to 38 years), and all of them were primiparas with singleton pregnancy. Among the 12 pregnant women, only 7 cases (7/12) were suspected of DUL by imaging examination during pregnancy. Five cases (5/12) only showed multiple uterine fibroids by ultrasound and magnetic resonance imaging during pregnancy, which were finally diagnosed according to intraoperative exploration. Five cases (5/12) of DUL had signs of threatened abortion or threatened preterm birth such as uterine contraction and bleeding during pregnancy, including 3 cases of preterm birth (2 cases of spontaneous preterm birth and 1 case of iatrogenic preterm birth due to prenatal hemorrhage). Among the 12 pregnant women with DUL, 2 cases (2/12) had abnormal fetal position, 3 cases (3/12) had placental adhesion, and 1 case (1/12) had fibroid degeneration. Among the 12 pregnant women with DUL, 9 cases (9/12) were delivered by cesarean section, of which 3 cases were converted to cesarean section because of failed trial of labor, and 6 cases were directly terminated by cesarean section because of abnormal fetal position or previous myomectomy history. Postpartum hemorrhage occurred in 5 cases (5/12), including 4 cases of severe postpartum hemorrhage, and uterine tamponade had good hemostatic effect. Three cases (3/12) had fever after operation or postpartum. All the 12 pregnant women were discharged in a stable condition. Among the 12 neonates, 2 (2/12) were transferred to the department of pediatrics due to premature birth and finally discharged smoothly. <b>Conclusions:</b> Pregnancy complicated with DUL is a high-risk pregnancy, which increases the risk of complications during gestation, delivery and postpartum. Uterine cavity compression hemostasis may be an effective measure to deal with postpartum hemorrhage.</p>","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 12","pages":"926-933"},"PeriodicalIF":0.0,"publicationDate":"2025-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145848685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Chinese Expert Consensus on GnRH-a in Obstetrics and Gynecology]. [中国妇产科GnRH-a专家共识]。
Pub Date : 2025-12-25 DOI: 10.3760/cma.j.cn112141-20250529-00244
J H Lang, J H Leng, Q Yang, R Li, K Q Hua, G N Zhang, W W Cheng, C D Liu, S Z Yao, Y Dai, X L Fang, H Jiang, Z Q Liang, C Peng, R C Chian, G Y Wang, L J Wang, B R Xia, H Xu, T M Zhang, S M Zhou, Y F Xu, Y J Zhu, W Di
{"title":"[Chinese Expert Consensus on GnRH-a in Obstetrics and Gynecology].","authors":"J H Lang, J H Leng, Q Yang, R Li, K Q Hua, G N Zhang, W W Cheng, C D Liu, S Z Yao, Y Dai, X L Fang, H Jiang, Z Q Liang, C Peng, R C Chian, G Y Wang, L J Wang, B R Xia, H Xu, T M Zhang, S M Zhou, Y F Xu, Y J Zhu, W Di","doi":"10.3760/cma.j.cn112141-20250529-00244","DOIUrl":"https://doi.org/10.3760/cma.j.cn112141-20250529-00244","url":null,"abstract":"","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 12","pages":"913-925"},"PeriodicalIF":0.0,"publicationDate":"2025-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145849051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Analysis of body composition in infertile patients with endometriosis complicated with endometrial polyps]. 【子宫内膜异位症合并子宫内膜息肉不孕症患者体成分分析】。
Pub Date : 2025-12-25 DOI: 10.3760/cma.j.cn112141-20250428-00177
X Feng, X Qin, F Tan, D M Xu, Q H Qu, L J Hao

Objective: To investigate the risk factors of endometrial polyps (EP) in patients with endometriosis (EM) and to analyze the predictive value of body composition measurement for EP. Methods: From January 1st, 2022 to June 30th, 2024, patients with EM who underwent hysteroscopy combined with laparoscopy in Chongqing Health Center for Women and Children due to "infertility" were enrolled. According to whether they had EP or not, they were divided into EP group and non-EP group. The general data and body composition (including skeletal muscle mass, body fat mass, body fat percentage and visceral fat level, waist-to-hip ratio, neck circumference, chest circumference, arm circumference, thigh circumference, etc.) of the two groups were compared. Univariate and multivariate logistic regression were used to analyze the high-risk factors of EP in infertile patients with EM. Body type was classified according to body fat percentage combined with lean body mass index. Body type classification and normal weight obesity rate were compared between the EP group and the non-EP group. Results: (1) A total of 180 patients with EM were enrolled, including 77 patients (42.8%, 77/180) in the EP group and 103 (57.2%, 103/180) patients in the non-EP group. There were no significant differences in body mass index (BMI), fasting blood glucose and blood lipid levels between the two groups (all P>0.05). The incidence of primary infertility, body fat mass, body fat percentage, visceral fat level, and thigh circumference in the EP group were higher than those in the non-EP group, and the differences were statistically significant (all P<0.05). (2) Multivariate logistic regression analysis showed that age≥30 years old (OR=3.079, 95%CI: 1.594-5.947), primary infertility (OR=2.914, 95%CI: 1.482-5.729), visceral fat level ≥10 grade (OR=2.838, 95%CI: 1.584-5.729) were the risk factors of EP in infertile patients with EM (all P<0.05). (3) In the EP group, there were no significant differences in BMI and body composition between single and multiple polyps, and between the largest polyp diameter <1 cm and ≥1 cm (all P>0.05). (4) The proportion of obese and puffy type in the EP group was higher than that in the non-EP group, and the difference in body type classification between the two groups was statistically significant (P=0.026). The proportion of patients with normal weight obesity in the EP group was significantly higher than that in the non-EP group [92.1% (35/38) vs 64.3% (36/56); χ2=9.480, P=0.002]. Conclusions: The occurrence of EP in infertile patients with EM is closely related to the increase of body fat mass, body fat percentage and visceral fat level, but not to BMI. The measurement of body composition is of great value for assessing the hidden obesity in infertile patients with EM.

目的:探讨子宫内膜异位症(EM)患者发生子宫内膜息肉(EP)的危险因素,并分析体成分测定对EP的预测价值。方法:选取2022年1月1日至2024年6月30日在重庆市妇幼保健院因“不孕症”行宫腔镜联合腹腔镜检查的EM患者。根据是否有EP分为EP组和无EP组。比较两组的一般资料及身体组成(包括骨骼肌量、体脂量、体脂百分比及内脏脂肪水平、腰臀比、颈围、胸围、臂围、大腿围等)。采用单因素和多因素logistic回归分析不孕合并EM患者发生EP的高危因素,根据体脂率结合瘦体质指数对体质进行分类。比较EP组与非EP组的体型分型及正常体重肥胖率。结果:(1)共纳入180例EM患者,EP组77例(42.8%,77/180),非EP组103例(57.2%,103/180)。两组患者体重指数(BMI)、空腹血糖、血脂水平差异均无统计学意义(P < 0.05)。EP组原发性不孕症发生率、体脂质量、体脂百分比、内脏脂肪水平、大腿围围均高于非EP组,差异均有统计学意义(均POR=3.079, 95%CI: 1.594-5.947)、原发性不孕症(OR=2.914, 95%CI: 1.482-5.729)、内脏脂肪水平≥10级(OR=2.838, 95%CI: 1.584-5.729)是EM合并不孕患者发生EP的危险因素(均ppbb0 0.05)。(4) EP组肥胖、浮肿型比例高于非EP组,两组在体型分类上差异有统计学意义(P=0.026)。EP组体重正常肥胖患者比例显著高于非EP组[92.1% (35/38)vs 64.3% (36/56);χ2 = 9.480,P = 0.002)。结论:不孕EM患者EP的发生与体脂量、体脂率、内脏脂肪水平的增加密切相关,而与BMI无关。体成分的测定对EM不孕症患者隐性肥胖的评估具有重要价值。
{"title":"[Analysis of body composition in infertile patients with endometriosis complicated with endometrial polyps].","authors":"X Feng, X Qin, F Tan, D M Xu, Q H Qu, L J Hao","doi":"10.3760/cma.j.cn112141-20250428-00177","DOIUrl":"https://doi.org/10.3760/cma.j.cn112141-20250428-00177","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the risk factors of endometrial polyps (EP) in patients with endometriosis (EM) and to analyze the predictive value of body composition measurement for EP. <b>Methods:</b> From January 1st, 2022 to June 30th, 2024, patients with EM who underwent hysteroscopy combined with laparoscopy in Chongqing Health Center for Women and Children due to \"infertility\" were enrolled. According to whether they had EP or not, they were divided into EP group and non-EP group. The general data and body composition (including skeletal muscle mass, body fat mass, body fat percentage and visceral fat level, waist-to-hip ratio, neck circumference, chest circumference, arm circumference, thigh circumference, etc.) of the two groups were compared. Univariate and multivariate logistic regression were used to analyze the high-risk factors of EP in infertile patients with EM. Body type was classified according to body fat percentage combined with lean body mass index. Body type classification and normal weight obesity rate were compared between the EP group and the non-EP group. <b>Results:</b> (1) A total of 180 patients with EM were enrolled, including 77 patients (42.8%, 77/180) in the EP group and 103 (57.2%, 103/180) patients in the non-EP group. There were no significant differences in body mass index (BMI), fasting blood glucose and blood lipid levels between the two groups (all <i>P</i>>0.05). The incidence of primary infertility, body fat mass, body fat percentage, visceral fat level, and thigh circumference in the EP group were higher than those in the non-EP group, and the differences were statistically significant (all <i>P</i><0.05). (2) Multivariate logistic regression analysis showed that age≥30 years old (<i>OR</i>=3.079, 95%<i>CI</i>: 1.594-5.947), primary infertility (<i>OR</i>=2.914, 95%<i>CI</i>: 1.482-5.729), visceral fat level ≥10 grade (<i>OR</i>=2.838, 95%<i>CI</i>: 1.584-5.729) were the risk factors of EP in infertile patients with EM (all <i>P</i><0.05). (3) In the EP group, there were no significant differences in BMI and body composition between single and multiple polyps, and between the largest polyp diameter <1 cm and ≥1 cm (all <i>P</i>>0.05). (4) The proportion of obese and puffy type in the EP group was higher than that in the non-EP group, and the difference in body type classification between the two groups was statistically significant (<i>P</i>=0.026). The proportion of patients with normal weight obesity in the EP group was significantly higher than that in the non-EP group [92.1% (35/38) <i>vs</i> 64.3% (36/56); <i>χ</i><sup>2</sup>=9.480, <i>P</i>=0.002]. <b>Conclusions:</b> The occurrence of EP in infertile patients with EM is closely related to the increase of body fat mass, body fat percentage and visceral fat level, but not to BMI. The measurement of body composition is of great value for assessing the hidden obesity in infertile patients with EM.</p>","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 12","pages":"951-957"},"PeriodicalIF":0.0,"publicationDate":"2025-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145849056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Efficacy of low-dose mifepristone in patients with thrombotic disorders complicated by heavy menstrual bleeding]. [低剂量米非司酮治疗血栓性疾病合并月经大出血的疗效]。
Pub Date : 2025-12-25 DOI: 10.3760/cma.j.cn112141-20250415-00149
X L Jiang, M Y Zhang, H N Su, X Yang
<p><p><b>Objective:</b> To evaluate the efficacy and safety of low-dose mifepristone (10-25 mg) in patients with thromboembolic disorders complicated by heavy menstrual bleeding (HMB). <b>Methods:</b> The data of 13 patients (median age:37 years) with thrombotic disorders and HMB treated with low-dose mifepristone in Peking University People's Hospital from January 2020 to March 2025 were retrospectively analyzed. The changes of acute bleeding control, menstrual blood loss [assessed by pictorial blood loss assessment chart (PBAC)], hemoglobin level, coagulation function and quality of life [assessed by menorrhagia multi-attribute scale (MMAS)] were evaluated. <b>Results:</b> (1) Among the 13 patients, venous thrombosis occurred in 8 cases (8/13), arterial thrombosis in 3 cases (3/13), and other types of thrombosis in 2 cases (2/13), including 1 case of local thrombosis after stent placement for anastomotic stenosis after renal transplantation, requiring long-term aspirin and clopidogrel, and 1 case of arteriovenous fistula thrombosis in a renal failure patient with long-term dialysis. (2) Nine patients (9/13) received antithrombotic medication, 1 patient (1/13) received inferior vena cava filter, and 3 patients (3/13) did not receive antithrombotic therapy due to platelet count <50×10⁹/L and high risk of bleeding. (3) Management of acute bleeding stage: 6 patients with massive vaginal bleeding in emergency department were treated with dose reduction or withdrawal of antithrombotic drugs, 5 cases were treated with intrauterine Foley balloon compression hemostasis combined with mifepristone, 1 case was treated with oral norethindrone combined with mifepristone, and the bleeding was successfully stopped, and the antithrombotic therapy was resumed after 1-2 days. (4) Mifepristone treatment (median course: 6 months): 7 patients without bleeding were treated with oral mifepristone directly. All patients had amenorrhea after 1 month of treatment, and PBAC score (1, 3, 6 months), hemoglobin level and quality of life were significantly improved (all <i>P</i><0.05). During the follow-up period, there was no recurrence or new onset of thrombosis, and there were no statistically significant differences in coagulation function indexes (including prothrombin time, activated partial thromboplastin time, fibrinogen) compared with those before treatment (all <i>P</i>>0.05). The level of D-dimer was lower than that before treatment, considering that it was related to the control of thrombotic diseases. Patients were subsequently transitioned to other modalities for long-term menstrual management. <b>Conclusions:</b> Low-dose mifepristone is a viable bridging therapy for patients with thromboembolic disorders and HMB. It effectively induces amenorrhea, enabling patients to safely navigate high-risk periods for both thrombosis and bleeding without significantly impacting coagulation function. This approach facilitates subsequent long-term menstrual management and tr
目的:评价低剂量米非司酮(10 ~ 25mg)治疗血栓栓塞性疾病合并月经大出血(HMB)的疗效和安全性。方法:回顾性分析2020年1月至2025年3月北京大学人民医院小剂量米非司酮治疗的13例血栓性疾病合并HMB患者(中位年龄:37岁)的资料。观察两组患者急性出血控制、月经失血量(PBAC)、血红蛋白水平、凝血功能及生活质量(MMAS)的变化情况。结果:(1)13例患者中,静脉血栓8例(8/13),动脉血栓3例(3/13),其他类型血栓2例(2/13),其中肾移植术后吻合口狭窄置入术后局部血栓1例,需长期服用阿司匹林和氯吡格雷;1例肾功能衰竭长期透析患者出现动静脉瘘血栓形成。(2) 9例(9/13)患者接受了抗栓药物治疗,1例(1/13)患者接受了下腔静脉过滤器治疗,3例(3/13)患者因血小板计数PP(0.05)未接受抗栓治疗。d -二聚体水平较治疗前降低,考虑其与血栓性疾病的控制有关。患者随后转为其他方式进行长期月经管理。结论:小剂量米非司酮是治疗血栓栓塞性疾病和HMB患者的一种可行的桥接疗法。它有效地诱导闭经,使患者能够安全地度过血栓和出血的高危期,而不会显著影响凝血功能。这种方法有助于后续长期月经管理和治疗原发性血栓栓塞性疾病,最终改善患者预后。
{"title":"[Efficacy of low-dose mifepristone in patients with thrombotic disorders complicated by heavy menstrual bleeding].","authors":"X L Jiang, M Y Zhang, H N Su, X Yang","doi":"10.3760/cma.j.cn112141-20250415-00149","DOIUrl":"https://doi.org/10.3760/cma.j.cn112141-20250415-00149","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To evaluate the efficacy and safety of low-dose mifepristone (10-25 mg) in patients with thromboembolic disorders complicated by heavy menstrual bleeding (HMB). &lt;b&gt;Methods:&lt;/b&gt; The data of 13 patients (median age:37 years) with thrombotic disorders and HMB treated with low-dose mifepristone in Peking University People's Hospital from January 2020 to March 2025 were retrospectively analyzed. The changes of acute bleeding control, menstrual blood loss [assessed by pictorial blood loss assessment chart (PBAC)], hemoglobin level, coagulation function and quality of life [assessed by menorrhagia multi-attribute scale (MMAS)] were evaluated. &lt;b&gt;Results:&lt;/b&gt; (1) Among the 13 patients, venous thrombosis occurred in 8 cases (8/13), arterial thrombosis in 3 cases (3/13), and other types of thrombosis in 2 cases (2/13), including 1 case of local thrombosis after stent placement for anastomotic stenosis after renal transplantation, requiring long-term aspirin and clopidogrel, and 1 case of arteriovenous fistula thrombosis in a renal failure patient with long-term dialysis. (2) Nine patients (9/13) received antithrombotic medication, 1 patient (1/13) received inferior vena cava filter, and 3 patients (3/13) did not receive antithrombotic therapy due to platelet count &lt;50×10⁹/L and high risk of bleeding. (3) Management of acute bleeding stage: 6 patients with massive vaginal bleeding in emergency department were treated with dose reduction or withdrawal of antithrombotic drugs, 5 cases were treated with intrauterine Foley balloon compression hemostasis combined with mifepristone, 1 case was treated with oral norethindrone combined with mifepristone, and the bleeding was successfully stopped, and the antithrombotic therapy was resumed after 1-2 days. (4) Mifepristone treatment (median course: 6 months): 7 patients without bleeding were treated with oral mifepristone directly. All patients had amenorrhea after 1 month of treatment, and PBAC score (1, 3, 6 months), hemoglobin level and quality of life were significantly improved (all &lt;i&gt;P&lt;/i&gt;&lt;0.05). During the follow-up period, there was no recurrence or new onset of thrombosis, and there were no statistically significant differences in coagulation function indexes (including prothrombin time, activated partial thromboplastin time, fibrinogen) compared with those before treatment (all &lt;i&gt;P&lt;/i&gt;&gt;0.05). The level of D-dimer was lower than that before treatment, considering that it was related to the control of thrombotic diseases. Patients were subsequently transitioned to other modalities for long-term menstrual management. &lt;b&gt;Conclusions:&lt;/b&gt; Low-dose mifepristone is a viable bridging therapy for patients with thromboembolic disorders and HMB. It effectively induces amenorrhea, enabling patients to safely navigate high-risk periods for both thrombosis and bleeding without significantly impacting coagulation function. This approach facilitates subsequent long-term menstrual management and tr","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 12","pages":"943-950"},"PeriodicalIF":0.0,"publicationDate":"2025-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145848854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
中华妇产科杂志
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1